-
Article
Open AccessSummary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, cau...
-
Article
Open AccessBiomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or wit...
-
Article
Open AccessEvaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
For many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurren...
-
Article
Open AccessAnalysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired ...
-
Article
Open AccessIntegrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. Only a fraction of NSCLC harbor actionable driver mutations and there is an urgent need for patient-derived model systems tha...
-
Article
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data
Small cell lung cancer (SCLC) is a highly fatal disease associated with significant morbidity, with a need for real-world symptom and health utility score (HUS) data. HUS can be measured using an EQ-5D-5L ques...
-
Article
A drug discovery platform to identify compounds that inhibit EGFR triple mutants
Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due to their role in disease. Historically, therapeutics targeting RTKs have been identified using in vitro kinase assays...
-
Article
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
Christopher Amos and colleagues perform genome-wide association analysis for lung cancer using cohorts genotyped on the OncoArray and combing these with existing data. They identify 18 loci, 10 of which are ne...
-
Article
Open AccessTRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer
Non-small-cell lung carcinoma (NSCLC) accounts for 85% of malignant lung tumors and is the leading cause of cancer deaths. Our group previously identified Tripartite Motif 14 (TRIM14) as a component of a prognost...
-
Article
Open AccessMolecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
The clinical utility of molecular profiling of tumor tissue to guide treatment of patients with advanced solid tumors is unknown. Our objectives were to evaluate the frequency of genomic alterations, clinical ...
-
Article
Open AccessClinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in predicting out...
-
Article
Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact
Cancer results from processes prone to selective pressure and dysregulation acting along the sequence-to-phenotype continuum DNA→RNA→protein→disease. However, the extent to which cancer is a manifestation of t...
-
Article
Open AccessActivity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselect...
-
Article
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer
Panobinostat is a potent oral pan-deacetylase inhibitor with promising clinical activity in hematologic malignancies. Panobinostat was shown to inhibit CYP2D6 activity in vitro; thus understanding the magnitud...
-
Article
Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
Based on meta-analyses and the results of several trials, adjuvant chemotherapy is currently recommended for stage II and stage III non-small cell lung cancer (NSCLC) patients after complete tumor resection, a...
-
Article
Open AccessExploiting the noise: improving biomarkers with ensembles of data analysis methodologies
The advent of personalized medicine requires robust, reproducible biomarkers that indicate which treatment will maximize therapeutic benefit while minimizing side effects and costs. Numerous molecular signatur...
-
Article
Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer
Although women have an increased susceptibility to lung cancer, they also have a favorable clinical outcome. This may in part be due to female specific genetic and hormonal factors. In the present study, expre...
-
Article
Open AccessLung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors
We conducted a case-control study in the greater Toronto area to evaluate potential lung cancer risk factors including environmental tobacco smoke (ETS) exposure, family history of cancer, indoor air pollution...
-
Article
Resident preparedness in discussing prognosis in patients with advanced lung cancer
Teaching delivery of bad news is part of the standard medical school curriculum. Lung cancer is a common disease with poor outcomes; therefore, “poor prognosis” discussions occur frequently. Trainee preparedne...
-
Chapter
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer
Inhibition of the epidermal growth factor receptor (EGFR) has become a standard target in the treatment of non-small cell lung cancer (NSCLC). This chapter summarizes the clinical trials that have been perform...
